Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Clinical Hematology International
|
December 29, 2025
Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in Sweden
Vincent Luong, Muhammad Kashif, Katarina Uttervall, et al.
American Journal of Hematology
|
April 26, 2021
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
Hareth Nahi, Muhammad Kashif, Monika Klimkowska, et al.
European Journal of Haematology
|
May 26, 2017
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
Hareth Nahi, Anna Genell, Göran Wålinder, et al.
British Journal of Haematology
|
December 10, 2013
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
Johan Liwing, Katarina Uttervall, Johan Lund, et al.
Cancers
|
March 13, 2024
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Anu Partanen, Anders Waage, Valdas Peceliunas, et al.
Haematologica
|
March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
Katarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
The New England Journal of Medicine
|
December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Clinical Hematology International
|
December 29, 2025
Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in Sweden
Vincent Luong, Muhammad Kashif, Katarina Uttervall, et al.
American Journal of Hematology
|
April 26, 2021
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
Hareth Nahi, Muhammad Kashif, Monika Klimkowska, et al.
European Journal of Haematology
|
May 26, 2017
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
Hareth Nahi, Anna Genell, Göran Wålinder, et al.
British Journal of Haematology
|
December 10, 2013
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
Johan Liwing, Katarina Uttervall, Johan Lund, et al.
Cancers
|
March 13, 2024
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Anu Partanen, Anders Waage, Valdas Peceliunas, et al.
Haematologica
|
March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
Katarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
The New England Journal of Medicine
|
December 9, 2024
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Meletios A Dimopoulos, Peter M Voorhees, Fredrik Schjesvold, et al.
Page
of 2